Homoeopathy in vitiligo

Phase 2

Completed

• Conditions: Health Condition 1: null- Vitiligo

• Registration Number: CTRI/2013/08/003879
• Lead Sponsor: Mahesh Bhattacharyya Homeopathic Medical College and Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. Age between 5 yrs to 80 yrs

2. Both sexes

3. Giving written informed consent to join the study

4. VETF stage 1 & 2, spread (+1) to (-1), extent any.

5. VASI residual depigmentation 25-75%; units any.

6. Patients already undergoing regular oral/topical conventional therapy for vitiligo, provided the medications are stopped completely for at last 1 month prior registering for the study

Patients on life-saving conventional drug therapies, e.g. anti-diabetics, anti-hypertensives, thyroid drugs etc. for co-morbidities under control, will be continued.

Exclusion Criteria

1. VETF stage 0 and 3

2. VASI residual depigmentation 100%, 90% and 10%

3. Uncontrolled, unevaluated and/or complicated diabetes mellitus, hypertension, and other co-morbidities

4. Cases with other systemic unevaluated or uncontrolled diseases like cardiovascular, renal, gastro-intestinal, endocrinal, gynecological diseases etc. or systemic infections affecting quality of life or on other treatment therapies

5. Pregnancy, lactation and likelihood of pregnancy

6. Not giving consent to join the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vitiligo Area Scoring Index (VASI)Timepoint: 6 months

Secondary Outcome Measures

Name	Time	Method
Dermatological Life Quality Index (DLQI)Timepoint: 6 months;Vitiligo European Task Force (VETF)Timepoint: 6 months